Analyst Group Comment on Circio’s H1 Report for 2026 and R&D-update
Circio Holding ASA (”Circio” or ”the Company”) published its first half report for 2026 on the 31st of August 2026, followed by a webcast with a financial and R&D update on the 1st of September 2026.
The following are key events that we have chosen to highlight from the recent news flow:
- circVec 5.0 has the potential of 200x or more versus conventional AAV – possibly making it a game changer within gene therapy
- circVec’s expression advantage confirmed with a therapeutic gene in heart (LAMP2B)
- 10–60x higher expression than conventional AAV in CNS across three separate delivery routes
- Durable expression achieved with a T-cell targeting LNP at all three dose levels tested, including the lowest
- Cash and short-term investments of NOK 539.0m (6.3) after approx. NOK 620m raised during H1-26, extending the runway into 2030
- 23 active R&D collaborations, with the stated aim of a first partnering deal carrying a cash payment during 2027
In summary, Analyst Group considers H1-26 to have been the most productive six-month period in Circio’s history since the repositioning around circular RNA, with R&D, partnering and financing each advancing materially. The expression advantage now reaches up to 60x across heart, eye and CNS, is confirmed with a therapeutic gene, and has a credible route toward a further step change through circVec 5.0. The collaboration portfolio has grown to 23 active arrangements including the fully funded top-5 pharma feasibility study, while NOK 539.0m in liquidity removes the funding question into 2030. The circVec 5.0 in vivo data speaks to scale, as a validated 200x construct would broaden the indication scope a licensee could realistically pursue and support terms above the platform-licensing benchmarks currently applied. The heart and eye disease-model results, alongside data from the big pharma CNS collaboration, govern probability and timing, marking the transition from reporter-level proof-of-concept to disease-relevant efficacy on which partner engagement depends. Converting either into a first agreement carrying a cash payment remains Circio’s stated target for 2027. Should the data deliver, Circio would enter licensing discussions with a financial runway to 2030 and a technology that has no established direct competitor in DNA-based, vector-encoded circular RNA expression, a distinction worth drawing, since the recent acquisitions in the field involved synthetic circular RNA delivered as RNA rather than produced inside the cell.
Read Analyst Group’s comment here
About Analyst Group: One of Sweden's leading equity research boutiques with focus on small and medium-sized listed companies.
Read more about Analyst Group
This is a press release from Analyst Group regarding the publication of a comment on Circio Holding. Readers may assume that Analyst Group has received compensation for making the comment. The Company has not been given an opportunity to influence the parts where Analyst Group has had opinions about the Company, future valuation or anything else that could be considered a subjective assessment.